Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 10
2.1 Disease Introduction 10
2.2 Epidemiology 11
2.3 Symptoms 12
2.3.1 Skin Manifestations 12
2.3.2 Psychological Impact 12
2.4 Etiology, Co-morbidities and Risk Factors 13
2.4.1 Genetics 13
2.4.2 Psoriatic Arthritis 13
2.4.3 Mental Health Disorders 13
2.4.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 14
2.4.5 Infections 15
2.4.6 Koebner Phenomenon 15
2.4.7 Other Immune-Mediated Diseases 15
2.5 Pathophysiology 15
2.6 Diagnosis 16
2.7 Prognosis 16
2.8 Treatment and Management 16
2.8.1 Pharmacological Therapies 17
2.8.2 Non-pharmacological Therapies 18
2.8.3 Combination and Rotational Therapies 19
2.8.4 Quality of Life Assessments 19
3 Marketed Products 20
3.1 Overview 20
3.1.1 Tremfya (guselkumab) – Janssen Biotech 21
3.1.2 Cosentyx (secukinumab) – Novartis 22
3.1.3 Otezla (apremilast) – Celgene 24
3.1.4 Alzumab (Itolizumab) – Biocon 25
3.1.5 Diavobet (calcipotriene and betamethasone dipropionate) – LEO Pharma 26
3.1.6 Lumicef (brodalumab) – Kyowa Hakko Kirin 27
3.1.7 Taltz (ixekizumab) – Eli Lilly 28
3.1.8 Stelara (ustekinumab) – Janssen Biotech 29
3.1.9 Enbrel (Etanercept) – Amgen 31
3.1.10 Remicade (Infliximab) – Janssen Biotech 32
3.1.11 Humira (Adalimumab) – AbbVie 33
3.1.12 Methotrexate 34
3.1.13 Cyclosporine 35
3.1.14 Acitretin 37
3.2 Comparative Efficacy and Safety of Marketed Products 38
4 Pipeline Analysis 40
4.1 Overview 40
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 41
4.3 Pipeline by Molecular Target 42
4.4 Promising Pipeline Candidates 44
4.4.1 Tildrakizumab – Sun Pharma 44
4.4.2 Risankizumab – AbbVie 46
4.4.3 Tapinarof – Welichem Biotech 48
4.4.4 Bimekizumab – UCB 49
4.4.5 Certolizumab Pegol – UCB 51
4.5 Comparative Efficacy and Safety of Pipeline Products 53
4.6 Product Competitiveness Framework 54
5 Clinical Trial Analysis 56
5.1 Failure Rate 56
5.1.1 Overall Failure Rate 56
5.1.2 Failure Rate by Phase and Molecule Type 58
5.1.3 Failure Rate by Phase and Molecular Target 58
5.2 Clinical Trial Size 59
5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 59
5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 60
5.2.3 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development 61
5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 62
5.3 Clinical Trial Duration 63
5.3.1 Clinical Trial Duration by Molecule Type 63
5.3.2 Clinical Trial Duration by Molecular Target 64
5.4 Competitive Clinical Trials Metrics Analysis 65
6 Multi-scenario Forecast 67
6.1 Geographical Markets 67
6.2 Asia-Pacific Market 67
6.3 India 70
6.3.1 Treatment Usage Patterns 70
6.3.2 Annual Cost of Therapy 71
6.3.3 Market Size 72
6.4 China 73
6.4.1 Treatment Usage Patterns 73
6.4.2 Annual Cost of Therapy 74
6.4.3 Market Size 74
6.5 Australia 75
6.5.1 Treatment Usage Patterns 75
6.5.2 Annual Cost of Therapy 76
6.5.3 Market Size 77
6.6 South Korea 78
6.6.1 Treatment Usage Patterns 78
6.6.2 Annual Cost of Therapy 79
6.6.3 Market Size 80
6.7 Japan 81
6.7.1 Treatment Usage Patterns 81
6.7.2 Annual Cost of Therapy 82
6.7.3 Market Size 82
7 Drivers and Barriers 84
7.1 Drivers 84
7.1.1 Increasing Support and Assistance from the Healthcare Systems 84
7.1.2 Rising Prevalence 84
7.1.3 Potential for Innovative Pipeline Molecules to Address Significant Unmet Need 84
7.1.4 Increasing Acceptance of Biologics and Biosimilars 84
7.2 Barriers 85
7.2.1 Use of Phototherapy and Traditional Medicines 85
7.2.2 Low Compliance and Treatment Discontinuation 85
7.2.3 Regulatory Submissions and Clinical Trial Requirement 85
7.2.4 High Prices of Therapeutics to Slow Down Market Growth 85
7.2.5 Growing Competition to Hinder Uptake of Pipeline Drugs 86
8 Deals and Strategic Consolidations 87
8.1 Licensing Deals 87
8.1.1 Deals by Region and Value 87
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 88
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 89
8.1.4 Key Licensing Deals 92
8.2 Co-development Deals 94
8.2.1 Deals by Region and Value 94
8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 95
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 95
8.2.4 Key Co-development Deals 98
9 Appendix 100
9.1 All Pipeline Drugs by Stage of Development 100
9.1.1 Discovery 100
9.1.2 Preclinical 102
9.1.3 IND/CTA-filed 105
9.1.4 Phase I 106
9.1.5 Phase II 107
9.1.6 Phase III 109
9.1.7 Pre-registration 110
9.2 Market Forecasts to 2024 110
9.2.1 Asia-Pacific 110
9.2.2 India 111
9.2.3 China 111
9.2.4 Australia 111
9.2.5 South Korea 112
9.2.6 Japan 112
9.3 Bibliography 112
9.4 Abbreviations 120
9.5 Research Methodology 121
9.5.1 Secondary Research 122
9.5.2 Marketed Product Profiles 122
9.5.3 Late-Stage Pipeline Candidates 122
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 122
9.5.5 Product Competitiveness Framework 123
9.5.6 Pipeline Analysis 123
9.5.7 Forecasting Model 123
9.5.8 Deals Data Analysis 124
9.6 Contact Us 125
9.7 Disclaimer 125